Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Topoisomerase I interactive agents.

C F Stewart1

  • 1Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38105, USA.

Cancer Chemotherapy and Biological Response Modifiers
|November 1, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Population Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade Gliomas.

CPT: pharmacometrics & systems pharmacology·2017
Same author

Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children With Pediatric Ependymoma.

CPT: pharmacometrics & systems pharmacology·2016
Same author

Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI.

British journal of cancer·2015
Same author

Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors.

Cancer chemotherapy and pharmacology·2014
Same author

Deriving therapies for children with primary CNS tumors using pharmacokinetic modeling and simulation of cerebral microdialysis data.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2013
Same author

The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer.

Clinical pharmacology and therapeutics·2013
Same journal

Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases.

Cancer chemotherapy and biological response modifiers·2005
Same journal

DNA vaccines for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Chemotherapy, cytokines, and biochemotherapy for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Current status of interferon-alpha in the treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
See all related articles

Understanding topoisomerase I structure and drug interactions is key for developing better cancer therapies. Further preclinical and clinical studies are crucial for optimizing existing drugs and ensuring rational development of new ones.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Topoisomerase I (TOP1) interactive agents are vital in cancer therapy.
  • Current agents like camptothecin derivatives have limitations.
  • Understanding TOP1's crystal structure and interaction mechanisms is crucial for drug development.

Purpose of the Study:

  • To highlight the importance of elucidating TOP1 crystal structure for rational drug design.
  • To emphasize the need for preclinical studies on TOP1 agent-induced cell death mechanisms.
  • To guide future clinical trials for optimizing existing TOP1 inhibitors and developing new analogs.

Main Methods:

  • Review of current knowledge on topoisomerase I interactive agents.
  • Analysis of preclinical study requirements for understanding drug mechanisms.

Related Experiment Videos

  • Discussion of clinical trial design considerations for combination regimens and dosing schedules.

    • Main Results:

    • Elucidating TOP1 structure is essential for designing improved therapeutic agents.
    • Preclinical studies are necessary to understand cell death pathways and optimize dosing.
    • Understanding mechanisms of toxicity, like irinotecan glucuronidation, can improve dosing and therapeutic index.

    Conclusions:

    • Rational development of TOP1 inhibitors requires detailed structural and mechanistic understanding.
    • Optimizing dosing schedules and combination regimens for current agents is a priority.
    • Rigorous preclinical evaluation is essential for all new TOP1 interactive agents entering development.